• 1
    Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 2009; 6: 71830.
  • 2
    Althuis MD, Fergenbaum JH, Garcia-Closas M, et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004; 13: 155868.
  • 3
    Walker R, Thompson AM. Prognostic and predictive factors in breast cancer: an overview. In: Walker R, Thompson AM, eds. Prognostic and predictive factors in breast cancer. London: Informa, 2008. 15.
  • 4
    World Cancer Research Fund, American Institure for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington DC: AICR, 2007.
  • 5
    Lawlor DA, Okasha M, Gunnell D, et al. Associations of adult measures of childhood growth with breast cancer: findings from the British Women's Heart and Health Study. Br J Cancer 2003; 89: 817.
  • 6
    Reiter EO, Rosenfeld RG. Normal and aberrant growth. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS, eds. Williams textbook of endocrinology. Philadelphia: Saunders, 2003. 1003114.
  • 7
    Speroff L, Fritz AM. Abnormal puberty and growth problems. In: Speroff L, Fritz MA, eds. Clinical gynecologic endocrinology and infertility. Baltimore: Lippincott Williams and Wilkins, 2005. 36299.
  • 8
    Gunnell D. Can adult anthropometry be used as a ‘biomarker’ for prenatal and childhood exposures? Int J Epidemiol 2002; 31: 3904.
  • 9
    Wadsworth ME, Hardy RJ, Paul AA, et al. Leg and trunk length at 43 years in relation to childhood health, diet and family circumstances; evidence from the 1946 national birth cohort. Int J Epidemiol 2002; 31: 38390.
  • 10
    Clarke BL, Khosla S. Female reproductive system and bone. Arch Biochem Biophys 2010; 503: 11828.
  • 11
    Onland-Moret NC, Peeters PH, van Gils CH, et al. Age at menarche in relation to adult height: the EPIC study. Am J Epidemiol 2005; 162: 62332.
  • 12
    Okasha M, McCarron P, Gunnell D, et al. Exposures in childhood, adolescence and early adulthood and breast cancer risk: a systematic review of the literature. Breast Cancer Res Treat 2003; 78: 22376.
  • 13
    Ruder EH, Dorgan JF, Kranz S, et al. Examining breast cancer growth and lifestyle risk factors: early life, childhood, and adolescence. Clin Breast Cancer 2008; 8: 33442.
  • 14
    Russo IH, Russo J. Pregnancy-induced changes in breast cancer risk. J Mammary Gland Biol Neoplasia 2011; 16: 22133.
  • 15
    Sellers TA, Davis J, Cerhan JR, et al. Interaction of waist/hip ratio and family history on the risk of hormone receptor-defined breast cancer in a prospective study of postmenopausal women. Am J Epidemiol 2002; 155: 22533.
  • 16
    Fagherazzi G, Vilier A, Boutron-Ruault MC, et al. Height, sitting height, and leg length in relation with breast cancer risk in the E3N cohort. Cancer Epidemiol Biomarkers Prev 2012; 21: 11715.
  • 17
    John EM, Sangaramoorthy M, Phipps AI, et al. Adult body size, hormone receptor status, and premenopausal breast cancer risk in a multiethnic population: the San Francisco Bay Area breast cancer study. Am J Epidemiol 2011; 173: 20116.
  • 18
    Borgquist S, Jirstrom K, Anagnostaki L, et al. Anthropometric factors in relation to different tumor biological subgroups of postmenopausal breast cancer. Int J Cancer 2009; 124: 40211.
  • 19
    Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011; 103: 25063.
  • 20
    Ma H, Bernstein L, Pike MC, et al. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 2006; 8: R43.
  • 21
    Colditz GA, Rosner BA, Chen WY, et al. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004; 96: 21828.
  • 22
    Macinnis RJ, English DR, Gertig DM, et al. Body size and composition and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 211725.
  • 23
    Riboli E, Kaaks R. The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 1997; 26: S614.
  • 24
    Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002; 5: 111324.
  • 25
    Haftenberger M, Lahmann PH, Panico S, et al. Overweight, obesity and fat distribution in 50- to 64-year-old participants in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr 2002; 5: 114762.
  • 26
    Spencer EA, Appleby PN, Davey GK, et al. Validity of self-reported height and weight in 4808 EPIC-Oxford participants. Public Health Nutr 2002; 5: 5615.
  • 27
    James RE, Lukanova A, Dossus L, et al. Postmenopausal serum sex steroids and risk of hormone receptor-positive and −negative breast cancer: a nested case-control study. Cancer Prev Res (Phila) 2011; 4: 162635.
  • 28
    Greenland S, Rothman KJ. Introduction to stratified analysis. In: Rothman KJ, Greenland S, Lash T, eds. Modern epidemiology. Philadelphia: Lippincott-Raven, 2008. 258302.
  • 29
    Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics 1995; 51: 52432.
  • 30
    Setiawan VW, Monroe KR, Wilkens LR, et al. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol 2009; 169: 12519.
  • 31
    Gunnell D, Okasha M, Smith GD, et al. Height, leg length, and cancer risk: a systematic review. Epidemiol Rev 2001; 23: 31342.
  • 32
    Newcomb PA, Trentham-Dietz A, Egan KM, et al. Fracture history and risk of breast and endometrial cancer. Am J Epidemiol 2001; 153: 10718.
  • 33
    Key TJ, Appleby PN, Reeves GK, et al. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010; 11: 53042.
  • 34
    Samani AA, Yakar S, LeRoith D, et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 2047.
  • 35
    Widen E, Silventoinen K, Sovio U, et al. Pubertal timing and growth influences cardiometabolic risk factors in adult males and females. Diabetes Care 2012;35:8506.
  • 36
    Davis AA, Kaklamani VG. Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer 2012; 2012: 809291.
  • 37
    Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 2005; 20: 205260.
  • 38
    Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res 2004; 6: 2405.
  • 39
    Asselin-Labat ML, Vaillant F, Sheridan JM, et al. Control of mammary stem cell function by steroid hormone signalling. Nature 2010; 465: 798802.
  • 40
    Ong KK, Ahmed ML, Dunger DB. Lessons from large population studies on timing and tempo of puberty (secular trends and relation to body size): the European trend. Mol Cell Endocrinol 2006; 254–255: 812.
  • 41
    The ESHRE Capri Workshop Group. Europe the continent with the lowest fertility. Hum Reprod Update 2010; 16: 590602.
  • 42
    Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982; 2: 573.
  • 43
    Ong KK. Early determinants of obesity. Endocr Dev 2010; 19: 5361.
  • 44
    Apter D, Reinila M, Vihko R. Some endocrine characteristics of early menarche, a risk factor for breast cancer, are preserved into adulthood. Int J Cancer 1989; 44: 7837.
  • 45
    Magne N, Toillon RA, Castadot P, et al. Different clinical impact of estradiol receptor determination according to the analytical method: a study on 1940 breast cancer patients over a period of 16 consecutive years. Breast Cancer Res Treat 2006; 95: 17984.
  • 46
    Welsh AW, Moeder CB, Kumar S, et al. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. J Clin Oncol 2011; 29: 297884.
  • 47
    Chu KC, Anderson WF, Fritz A, et al. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 2001; 92: 3745.
  • 48
    Yasui Y, Potter JD. The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 1999; 10: 4317.